Yantai Dongcheng Biochemicals: Announcement Regarding the Holding Subsidiary Receiving Drug Clinical Trial Approval Notification
Yantai Dongcheng Biochemicals: Announcement on the Obtaining of State Food and Drug Administration Approval for Technetium (99mTc) Tetrofosmin Injection
Yantai Dongcheng Biochemicals: Announcement Regarding the Launch of Operations at Hefei Nuclear Medicine Production Center.
Yantai Dongcheng Biochemicals: Announcement on the holding subsidiary obtaining a notice of approval for drug clinical trials
Yantai Dongcheng Biochemicals: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Yantai Dongcheng Pharmaceutical Group Co., Ltd.
Yantai Dongcheng Biochemicals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Yantai Dongcheng Biochemicals: Announcement on the subsidiary company being recognized as a specialized, special and new small and medium-sized enterprise in Hebei Province
Yantai Dongcheng Biochemicals: Announcement on the holding subsidiary obtaining a notice of approval for drug clinical trials
Yantai Dongcheng Biochemicals: Self-inspection form for the implementation of internal control rules
Yantai Dongcheng Biochemicals: Internal Control Self-Assessment Report
Yantai Dongcheng Biochemicals: First Special Meeting of Independent Directors of the 6th Board of Directors
Yantai Dongcheng Biochemicals: Notice on Using Idle Own Funds to Purchase Wealth Management Products
Yantai Dongcheng Biochemicals: 2023 Financial Results Report
Yantai Dongcheng Biochemicals: Announcement on preparing to accrue asset impairment
Yantai Dongcheng Biochemicals: Notice of Annual General Meeting of Shareholders
Yantai Dongcheng Biochemicals: Report of the Audit Committee on the performance of supervisory duties by accounting firms in 2023
Dongcheng Pharmaceutical: Announcement on the capital increase and stock expansion of the holding subsidiary to bring in investors
Dongcheng Pharmaceutical: Dongcheng Pharmaceutical: Announcement on the Wholly-owned Subsidiary's Subscription of XING2DIAGNOSTICS, INC. Convertible Bonds
Dongcheng Pharmaceutical: Announcement on subsidiary company capital increase and stock expansion and introduction of investors
Dongcheng Pharmaceutical: Announcement on the holding subsidiary passing the GMP compliance inspection
No Data